A scalable outpatient framework for BI-RADS 2–4B breast nodule management: an iodine–DMSO transdermal protocol
João Francisco Pollo Gaspary, Luis Felipe Dias Lopes, Fernanda Peron Gaspary, Carmen Brum Rosa, Antonio Geraldo Camara · 2026
Read A scalable outpatient framework for BI-RADS 2–4B breast nodule management: an iodine–DMSO transdermal protocol by João Francisco Pollo Gaspary, Luis Felipe Dias Lopes, Fernanda Peron Gaspary, Carmen Brum Rosa, Antonio Geraldo Camara (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13612448.txt.
Description
João Francisco Pollo Gaspary leads a five-author team designing a gentler path for women watching low-suspicion breast nodules. BI-RADS 2 to 4B lesions mean months of surveillance scans and anxiety, with no low-risk intervention in between. Their outpatient protocol paints a mixture of Lugol's iodine solution and DMSO on the skin, banking on iodine's redox effects and DMSO's skin-carrying power. Formal decision methods structured the design.
Synthesis singled out redox modulation, vessel responsiveness, and microenvironment stabilization as the plausible levers. Comparing delivery routes favored the skin. The final regimen, equal small volumes of each liquid twice weekly for five weeks, was tried in three exploratory BI-RADS 4B cases. Two nodules vanished on imaging, one staying clear at twelve months. A third responded partially and went to needle biopsy. No major side effects appeared. The authors stress the exploratory scale and call for controlled trials.
Catalog record
| CREATOR | João Francisco Pollo Gaspary, Luis Felipe Dias Lopes, Fernanda Peron Gaspary, Carmen Brum Rosa, Antonio Geraldo Camara |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 100 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |